Treatment of chronic cough: P2X3 receptor antagonists and beyond.
Pharmacol Ther
; 237: 108166, 2022 09.
Article
en En
| MEDLINE
| ID: mdl-35263649
ABSTRACT
For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiological mechanisms of CC, primarily the recognition of neuronal dysregulation in its aetiology, there appears to be a new hope for such patients. In this review we discuss the multitude of proposed pharmacological targets in CC, including the promising results produced by the antagonism of P2X3 receptors. We also assess the evidence of other peripherally acting pharmacolgical agents still in development.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tos
/
Antagonistas del Receptor Purinérgico P2X
Límite:
Humans
Idioma:
En
Revista:
Pharmacol Ther
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido